PMID- 19644473
OWN - NLM
STAT- MEDLINE
DCOM- 20090825
LR  - 20220409
IS  - 1474-1784 (Electronic)
IS  - 1474-1776 (Print)
IS  - 1474-1776 (Linking)
VI  - 8
IP  - 8
DP  - 2009 Aug
TI  - Targeting the phosphoinositide 3-kinase pathway in cancer.
PG  - 627-44
LID - 10.1038/nrd2926 [doi]
AB  - The phosphoinositide 3-kinase (PI3K) pathway is a key signal transduction system 
      that links oncogenes and multiple receptor classes to many essential cellular 
      functions, and is perhaps the most commonly activated signalling pathway in human 
      cancer. This pathway therefore presents both an opportunity and a challenge for 
      cancer therapy. Even as inhibitors that target PI3K isoforms and other major 
      nodes in the pathway, including AKT and mammalian target of rapamycin (mTOR), 
      reach clinical trials, major issues remain. Here, we highlight recent progress 
      that has been made in our understanding of the PI3K pathway and discuss the 
      potential of and challenges for the development of therapeutic agents that target 
      this pathway in cancer.
FAU - Liu, Pixu
AU  - Liu P
AD  - Department of Cancer Biology, Dana-Farber Cancer Institute, Pathology, Harvard 
      Medical School, Boston, MA 02115, USA.
FAU - Cheng, Hailing
AU  - Cheng H
FAU - Roberts, Thomas M
AU  - Roberts TM
FAU - Zhao, Jean J
AU  - Zhao JJ
LA  - eng
GR  - P50 CA089393-08/CA/NCI NIH HHS/United States
GR  - R01 CA134502/CA/NCI NIH HHS/United States
GR  - P01 CA050661-218165/CA/NCI NIH HHS/United States
GR  - CA089021/CA/NCI NIH HHS/United States
GR  - CA050661/CA/NCI NIH HHS/United States
GR  - R01 CA134502-03/CA/NCI NIH HHS/United States
GR  - P01 CA050661/CA/NCI NIH HHS/United States
GR  - RC2 CA148164-02/CA/NCI NIH HHS/United States
GR  - R37 CA030002-18/CA/NCI NIH HHS/United States
GR  - RC2 CA148164/CA/NCI NIH HHS/United States
GR  - CA030002/CA/NCI NIH HHS/United States
GR  - R37 CA030002/CA/NCI NIH HHS/United States
GR  - P50 CA089393/CA/NCI NIH HHS/United States
GR  - P50 CA089393-08S1/CA/NCI NIH HHS/United States
GR  - CA134502-01/CA/NCI NIH HHS/United States
GR  - R01 CA030002/CA/NCI NIH HHS/United States
GR  - P01 CA089021/CA/NCI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
PT  - Research Support, U.S. Gov't, Non-P.H.S.
PT  - Review
PL  - England
TA  - Nat Rev Drug Discov
JT  - Nature reviews. Drug discovery
JID - 101124171
RN  - 0 (Antineoplastic Agents)
RN  - 0 (Enzyme Inhibitors)
RN  - 0 (Phosphoinositide-3 Kinase Inhibitors)
RN  - EC 2.7.- (Protein Kinases)
RN  - EC 2.7.1.1 (MTOR protein, human)
RN  - EC 2.7.11.1 (Proto-Oncogene Proteins c-akt)
RN  - EC 2.7.11.1 (TOR Serine-Threonine Kinases)
SB  - IM
MH  - Animals
MH  - Antineoplastic Agents/*pharmacology/therapeutic use
MH  - Clinical Trials as Topic
MH  - Drug Delivery Systems
MH  - Enzyme Inhibitors/pharmacology/therapeutic use
MH  - Humans
MH  - Neoplasms/*drug therapy/enzymology
MH  - *Phosphoinositide-3 Kinase Inhibitors
MH  - Protein Kinases/drug effects/metabolism
MH  - Proto-Oncogene Proteins c-akt/antagonists & inhibitors
MH  - Signal Transduction/drug effects
MH  - TOR Serine-Threonine Kinases
PMC - PMC3142564
MID - NIHMS212276
EDAT- 2009/08/01 09:00
MHDA- 2009/08/26 09:00
PMCR- 2011/07/24
CRDT- 2009/08/01 09:00
PHST- 2009/08/01 09:00 [entrez]
PHST- 2009/08/01 09:00 [pubmed]
PHST- 2009/08/26 09:00 [medline]
PHST- 2011/07/24 00:00 [pmc-release]
AID - nrd2926 [pii]
AID - 10.1038/nrd2926 [doi]
PST - ppublish
SO  - Nat Rev Drug Discov. 2009 Aug;8(8):627-44. doi: 10.1038/nrd2926.